A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most ...

In the absence of trials, a post hoc analysis compared stereotactic body radiotherapy (SBRT) and high-dose-rate brachytherapy (HDR-BT) in intermediate-risk prostate cancer.

Kishan and colleagues found that men with PSA levels of 0.51-1.00 ng/mL had a reduction in mortality risk with the addition of hormone therapy (HR 0.72, 95% CI 0.54-0.96), as did those with PSA levels ...

PSA's February 2026 Price Hike Details PSA implemented these psa grading price increases in February 2026 to match surging ...

Many men believe that feeling tired, gaining weight, losing motivation, and struggling with libido is just part of getting older. It’s not.

Retail prices of regular milled rice increased in early February, while farmgate prices of palay also posted gains at the start of the year, data from the ...

A newer type of prostate cancer scan called 64 Cu-SAR-bisPSMA found more than twice as many cancer spots as a commonly used PSMA PET scan in men whose prostate-specific antigen (PSA) was rising after ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

More than 70% of patients with biochemically recurrent prostate cancer remained metastasis-free 5 years after PSMA PET/CT-guided salvage radiation therapy. Whole-pelvis radiation significantly ...